Mateon's CA4P Disappoints At Second Interim Analysis, More Data Awaited
A third interim analysis, in September, may clarify whether Mateon’s vascular disrupting agent is likely to be therapeutically useful as a new class of agents for ovarian cancer.
You may also be interested in...
Genocea shifts to preclinical neoantigen-based cancer vaccines rather than advance a Phase III-ready herpes program on its own and Mateon gives up on its lead drug as placebo outperforms. Also, Juno tops recent public company financings and new VC funds back early-stage firms.
FDA granted accelerated approval to PARP inhibitor Rubraca for treatment with BRCA-mutation positive ovarian cancer patients treated with two or more chemotherapies.
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.